Core Viewpoint - Shandong Pharmaceutical Glass reported a decline in both revenue and net profit for the third quarter of 2025, indicating challenges in the company's financial performance compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 1.027 billion yuan, a year-on-year decrease of 17.14% [1] - The net profit attributable to shareholders was 171 million yuan, down 30.15% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.2581 yuan [1] - For the first three quarters of 2025, total revenue reached 3.401 billion yuan, reflecting an 11.10% decline compared to the same period last year [1] - The net profit attributable to shareholders for the first three quarters was 542 million yuan, a decrease of 24.70% year-on-year [1] - Basic earnings per share for the first three quarters were 0.8174 yuan [1]